FY25 Results and Appendix 4E
Filed with ASX · · 6 pages · English
Summary by 6ix AI
The report highlights improvements in control capabilities and spin coherence times for its quantum chip, as well as developments in biosensor technology for medical diagnostics. The company reported a net loss for the year, with no dividends paid or proposed, and emphasized its strong cash position to support ongoing research and development. The filing also notes the appointment of a new CEO and the establishment of an Advisory Committee to guide the company's strategic direction.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Archer Materials Limited on 6ix
Story so far
Earlier from Archer Materials
- AXE to Unlock Scalable Potassium Sensor Production with IMEC
- Quarterly Activities Report & Appendix 4C
- TMR Sensor Functionality at Cryogenic Temperature
- Archer Advances Quantum Technology
- Biochip integrates with readout circuitry on a silicon chip
Later from Archer Materials
- AXE builds on EDMR breakthrough to advance qubit development
- Archer and Emergence partner to pursue graphene quantum tech
- Silicon Biochip meets performance and clinical requirements
- AXE & CSIRO - Quantum Machine Learning for fraud detection
- AXE achieves readout milestone towards qubit demonstration
Follow Archer Materials into a list and get an email when it puts out news.
Follow Archer Materials